We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 247 → 2 (-245)

100% less funds holding in top 10

Funds holding in top 10: 21 → 0 (-21)

100% less capital invested

Capital invested by funds: $4.73B → $42.1K (-$4.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 239

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-245
Holders Change %
-99.19%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-21
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
239
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$428M
2
BlackRock
BlackRock
New York
-$323M
3
BBA
Baker Bros. Advisors
New York
-$254M
4
PCM
Pentwater Capital Management
Florida
-$218M
5
State Street
State Street
Massachusetts
-$162M
Name Holding Trade Value Shares
Change 		Change in
Stake
NYLIM
51
New York Life Investment Management
New York
– -$22.2M -325,493 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
52
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$21.6M -316,521 Closed
Two Sigma Investments
53
Two Sigma Investments
New York
– -$21.4M -314,839 Closed
BNP Paribas Asset Management
54
BNP Paribas Asset Management
France
– -$19.4M -284,891 Closed
Renaissance Technologies
55
Renaissance Technologies
New York
– -$19.3M -283,700 Closed
D.E. Shaw & Co
56
D.E. Shaw & Co
New York
– -$19M -279,400 Closed
UBS Group
57
UBS Group
Switzerland
– -$18.9M -276,847 Closed
Bank of New York Mellon
58
Bank of New York Mellon
New York
– -$18.6M -272,788 Closed
Deutsche Bank
59
Deutsche Bank
Germany
– -$18.1M -265,681 Closed
MMA
60
Mizuho Markets Americas
New York
– -$17.4M -255,749 Closed
Tudor Investment Corp
61
Tudor Investment Corp
Connecticut
– -$17M -250,091 Closed
Schroder Investment Management Group
62
Schroder Investment Management Group
United Kingdom
– -$17M -249,107 Closed
Qube Research & Technologies (QRT)
63
Qube Research & Technologies (QRT)
United Kingdom
– -$16.9M -248,408 Closed
CCM
64
Chicago Capital Management
Illinois
– -$16.8M -246,246 Closed
UBS AM
65
UBS AM
Illinois
– -$16.7M -244,631 Closed
GCIA
66
Gabelli & Co Investment Advisers
New York
– -$15.8M -231,506 Closed
PMAM
67
Picton Mahoney Asset Management
Ontario, Canada
– -$15.1M -221,191 Closed
HF
68
HRT Financial
New York
– -$14.5M -213,168 Closed
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
– -$13.7M -201,624 Closed
SAM
70
Silphium Asset Management
United Kingdom
– -$13.6M -200,000 Closed
AAA
71
Affinity Asset Advisors
New York
– -$12.9M -190,000 Closed
HSBC Holdings
72
HSBC Holdings
United Kingdom
– -$12.9M -189,723 Closed
Bank of Montreal
73
Bank of Montreal
Ontario, Canada
– -$12.7K -186,080 Closed
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
– -$12.4M -182,817 Closed
State of Wisconsin Investment Board
75
State of Wisconsin Investment Board
Wisconsin
– -$12.3M -179,928 Closed
1 2
3
4 5

GBT Hedge Fund Activity: Q4 2022 in Review

2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.

Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.

  • 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
  • Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.

Based on aggregated 13F filings for Q4 2022.